Start Date
September 30, 2016
Primary Completion Date
October 31, 2019
Study Completion Date
October 31, 2020
G-202
G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
John Wayne Cancer Institute, Santa Monica
Lead Sponsor
Saint John's Cancer Institute
OTHER
GenSpera, Inc.
INDUSTRY